Clicky

Sanofi(SNYNF)

Description: Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.


Keywords: Clinical Medicine Drugs Diabetes Prostate Cancer Vaccines Rheumatoid Arthritis Arthritis Monoclonal Antibody Influenza Dialysis Multiple Sclerosis VIX Colorectal Cancer Health Care Products Osteoarthritis Insulin Atopic Dermatitis Cholesterol Dermatitis Metastatic Colorectal Cancer Allergic Rhinitis Rhinitis Sterol Meningitis E Combination Heparin Insomnia Sclerosis Axis Atrial Fibrillation Docetaxel Therapeutic Solutions Evotec Taxa Consumer Health Care Products Fabry Disease Gaucher Disease Insulin Glargine Mucopolysaccharidosis Acute Coronary Syndrome Aflibercept Mtr Pompe Disease Zara Iduronidase Lantus Lixisenatide Venous Thromboembolism Apidra Fibrillation Gaucher Hives Oxaliplatin Seasonal Allergic Rhinitis

Home Page: www.sanofi.com

46, avenue de la Grande Armée,
Paris, 75017
France
Phone: 33 1 53 77 40 00


Officers

Name Title
Mr. Paul Hudson CEO & Director
Mr. François-Xavier Roger Executive VP & CFO
Ms. Madeleine Roach Executive VP & Head of Business Operations
Mr. Laurent Gilhodes Principal Accounting Officer and Vice President of Corporate Accounting
Dr. Josephine Fubara Chief Science Officer of Consumer Health Care
Mr. Thomas Kudsk Larsen Head of Investor Relations
Mr. Dante Beccaria Global Compliance Officer & VP
Mr. Roy Papatheodorou Executive VP & General Counsel
Mr. Josep Catlla Head of Communications
Mr. Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 10.3199
Trailing PE: 25.0663
Price-to-Book MRQ: 1.5512
Price-to-Sales TTM: 2.5058
IPO Date:
Fiscal Year End: December
Full Time Employees: 86088
Back to stocks